Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Young adults with hostile attitudes may experience memory and thinking problems decades later

Young adults with hostile attitudes or those who don't cope well with stress may be at increased risk for experiencing memory and thinking problems decades later, according to a study published in the March 2, 2016, online issue of Neurology, the medical journal of the American Academy of Neurology.

7 Mar 2016

Drinking more coffee may reduce risk of multiple sclerosis

Drinking a lot of coffee every day--more than 900 ml (30 fluid ounces) or around six cups--is linked to a reduced risk of multiple sclerosis (MS), finds research published online in the Journal of Neurology Neurosurgery & Psychiatry.

7 Mar 2016

Childhood emotional abuse linked to adult migraine risk

Children who are emotionally abused may be more likely to experience migraines as young adults, according to a preliminary study released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016. The link between migraine and abuse was stronger for emotional abuse than for physical or sexual abuse in the study.

3 Mar 2016

Research shows nighttime lights may affect sleeping habits

If your neighborhood is well-lit at night, you may not be sleeping well, according to a study released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.

2 Mar 2016

Phase III study: Ocrelizumab significantly reduces disease activity in PPMS patients

Ocrelizumab (OCR) is a humanized monoclonal antibody that selectively targets CD20+B cells. In a randomized, double-blind, placebo-controlled Phase III study (ORATORIO), OCR significantly reduced disease activity in patients with primary progressive multiple sclerosis (PPMS).

27 Feb 2016

New drug shows promise against Huntington's disease

A drug that would be the first to target the cause of Huntington's disease (HD) is effective and safe when tested in mice and monkeys, according to data released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.

27 Feb 2016

Study: Most Ebola survivors experience brain symptoms more than six months after initial infection

Most of the 82 Ebola survivors in a new study from the world's largest Ebola outbreak had brain symptoms more than six months after the initial infection. The preliminary results will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.

25 Feb 2016

Study: Migraine, tension-type headaches may share genetic links with IBS

Migraine and tension-type headaches may share genetic links with irritable bowel syndrome (IBS), according to a preliminary study released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.

24 Feb 2016

Adapted yoga feasible, beneficial for adults with stroke or traumatic brain injury

A research team, led by an IU School of Health and Rehabilitation faculty member at Indiana University-Purdue University Indianapolis, has determined that adapted yoga is both feasible and beneficial for adults with stroke or traumatic brain injury.

23 Feb 2016

MDI Biological Laboratory scientist identifies potential drug therapy to reverse peripheral nerve damage

The Mount Desert Island Biological Laboratory has announced that assistant professor Sandra Rieger, Ph.D., has identified two drugs that could potentially be used to reverse peripheral nerve damage, or peripheral neuropathy, resulting from chemotherapy treatment for ovarian, breast, lung, pancreas and other cancers. The drugs also have potential applications for the treatment of peripheral nerve damage caused by diabetes, traumatic injuries and other conditions.

23 Feb 2016

Regulus reports net loss of $7.2 million for fourth quarter 2015

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the fourth quarter and full-year ended December 31, 2015 and provided a summary of recent corporate highlights.

23 Feb 2016

Calgary researchers develop new class of nanomedicines to treat autoimmune diseases

A new study from the University of Calgary could change the way researchers understand and treat autoimmune diseases such as type 1 diabetes, multiple sclerosis and rheumatoid arthritis.

22 Feb 2016

New study focuses on safety of using induced pluripotent stem cells in patients

A new study led by scientists at The Scripps Research Institute and the J. Craig Venter Institute shows that the act of creating pluripotent stem cells for clinical use is unlikely to pass on cancer-causing mutations to patients.

22 Feb 2016

Amarantus BioScience Holdings closes $3M investment

Amarantus BioScience Holdings, Inc., a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan diseases, today announced the closing of a $3M investment from an institutional investor. Under the terms of the agreement, the investor will be issued $3.3M worth of Series H Convertible Preferred Stock (including 10% original issue discount) from the Company and five year warrants exercisable for 13,200,000 shares of common stock at $0.40 per share.

22 Feb 2016

Wearable robotic exoskeleton may enable multiple sclerosis patients to walk more efficiently

Walking with a wearable robotic exoskeleton may enable people with multiple sclerosis to walk more efficiently by reducing the energy and muscle activity needed to walk, according to research presented this week at the Association for Academic Physiatrists Annual Meeting in Sacramento, Calif.

19 Feb 2016

Parvus' novel therapeutic approach employing nanomedicines published in Nature

Parvus Therapeutics today announced the publication in Nature of a seminal paper describing the discovery and applications of a novel therapeutic approach employing nanomedicines, referred to as "Navacims"TM, to reprogram white blood cells to become regulatory cells capable of blunting autoimmune responses and restoring the equilibrium of the immune system.

19 Feb 2016

Antibiotics may be linked to delirium and other brain problems

Antibiotics may be linked to a serious disruption in brain function, called delirium, and other brain problems, more than previously thought, according to a "Views and Reviews" article published in the February 17, 2016, online issue of Neurology, a medical journal of the American Academy of Neurology.

18 Feb 2016